Notice Number: NOT-NS-19-070

Key Dates
Release Date: June 19, 2019

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to inform potential applicants about a correction to the Application and Submission Information for PAR-18-543 , "CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional) ". The Application and Submission Information Section has been modified to include information that was erroneously omitted. This notice will be effective for the July 18, 2019 receipt date and subsequent due dates.

The correction applies to the sentence below (written in bold italics) in the Page Limitations of Section IV.2. Content and Form of Application Submission.

All page limitations described in the SF424 (R&R) SBIR/STTR Application Guide and the Table of Page Limits must be followed.

This sentence is corrected to read:

All page limitations described in the SF424 (R&R) SBIR/STTR Application Guide and the Table of Page Limits must be followed.

For this specific FOA, the Research Strategy section is limited to 30 pages.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Chris Boshoff, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]